Evidence map›Paper›PMID 26343962›Full record

ArticleVaccines2013

Nonclinical Development of BCG Replacement Vaccine Candidates.

Kamalakannan Velmurugan, Leander Grode, Rosemary Chang, Megan Fitzpatrick, Dominick Laddy, David Hokey, Steven Derrick, Sheldon Morris, David McCown, Reginald Kidd and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Safety and Immunogenicity of RecombinantInternational journal of molecular sciences · 2023
    Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Tuberculosis vaccine development: from classic to clinical candidates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Review
  15. Towards new TB vaccines.Seminars in immunopathology · 2020
    Review
  16. Vaccines · 2020
    Article
  17. Vaccine strategies for theNPJ vaccines · 2020
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Kamalakannan VelmuruganAeras, Rockville, MD 20850, USA. kvelmurugan@aeras.org.
Leander GrodeVakzine Projekt Management GmbH, Mellendorferstrasse 9, 30625 Hannover, Germany.
Rosemary ChangAeras, Rockville, MD 20850, USA.
Megan FitzpatrickAeras, Rockville, MD 20850, USA.
Dominick LaddyAeras, Rockville, MD 20850, USA.
David HokeyAeras, Rockville, MD 20850, USA.
Steven DerrickCenter for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
Sheldon MorrisCenter for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
David McCownAeras, Rockville, MD 20850, USA.
Reginald KiddAeras, Rockville, MD 20850, USA.
Martin GengenbacherMax Planck Institute for Infection Biology, Department of Immunology, Charitéplatz, 110117 Berlin, Germany.
Bernd EiseleVakzine Projekt Management GmbH, Mellendorferstrasse 9, 30625 Hannover, Germany.
Stefan H E KaufmannMax Planck Institute for Infection Biology, Department of Immunology, Charitéplatz, 110117 Berlin, Germany.
John FulkersonAeras, Rockville, MD 20850, USA.
Michael J BrennanAeras, Rockville, MD 20850, USA.
Aeras · USCenter for Biologics Evaluation and Research · USCharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The failure of current Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccines, given to neonates to protect against adult tuberculosis and the risk of using these live vaccines in HIV-infected infants, has emphasized the need for generating new, more efficacious and safer replacement vaccines. With the availability of genetic techniques for constructing recombinant BCG (rBCG) strains containing well-defined gene deletions or insertions, new vaccine candidates are under evaluation at both the preclinical and clinical stages of development. Since most BCG vaccines in use today were evaluated in clinical trials decades ago and are produced by outdated processes, the development of new BCG vaccines offers a number of advantages that include a modern well-defined manufacturing process along with state-of-the-art evaluation of safety and efficacy in target populations. We provide a description of the preclinical development of two novel rBCGs, VPM1002 that was constructed by adding a modified hly gene coding for the protein listeriolysin O (LLO) from Listeria monocytogenes and AERAS-422, which carries a modified pfoA gene coding for the protein perfringolysin O (PFO) from Clostridium perfringens, and three genes from Mycobacterium tuberculosis. Novel approaches like these should be helpful in generating stable and effective rBCG vaccine candidates that can be better characterized than traditional BCG vaccines.

Indexed as

live vaccinesMycobacterium tuberculosisrecombinant BCGtuberculosis

Identifiers

PMID26343962
PMCPMC4515585
OpenAlexW2075085840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.